[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ECSP066894A - Derivados de sulfonamida-tiazolpiridina como activadores de glucocinasa utiles en el tratamiento de diabetes de tipo 2 - Google Patents

Derivados de sulfonamida-tiazolpiridina como activadores de glucocinasa utiles en el tratamiento de diabetes de tipo 2

Info

Publication number
ECSP066894A
ECSP066894A EC2006006894A ECSP066894A ECSP066894A EC SP066894 A ECSP066894 A EC SP066894A EC 2006006894 A EC2006006894 A EC 2006006894A EC SP066894 A ECSP066894 A EC SP066894A EC SP066894 A ECSP066894 A EC SP066894A
Authority
EC
Ecuador
Prior art keywords
treatment
diabetes
type
thiazolpiridine
sulfonamide
Prior art date
Application number
EC2006006894A
Other languages
English (en)
Inventor
Gregory Raymond Bebernitz
Ramesh Chandra Gupta
Vikrant Vijaykumar Jagtap
Appaji Baburao Mandhare
Davinder Tuli
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ECSP066894A publication Critical patent/ECSP066894A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención proporciona compuestos de la fórmula (I), los cuales son activadores de la actividad de glucocinasa y, de esta manera, pueden ser empleados como agentes terapéuticos para el tratamiento de condiciones mediadas por glucocinasa. Por consiguiente, los compuestos de la fórmula (I) pueden ser empleados para la prevención y el tratamiento de tolerancia dañada a glucosa, diabetes de Tipo 2 y obesidad.
EC2006006894A 2004-04-02 2006-09-29 Derivados de sulfonamida-tiazolpiridina como activadores de glucocinasa utiles en el tratamiento de diabetes de tipo 2 ECSP066894A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55918404P 2004-04-02 2004-04-02

Publications (1)

Publication Number Publication Date
ECSP066894A true ECSP066894A (es) 2006-11-24

Family

ID=34963913

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006894A ECSP066894A (es) 2004-04-02 2006-09-29 Derivados de sulfonamida-tiazolpiridina como activadores de glucocinasa utiles en el tratamiento de diabetes de tipo 2

Country Status (19)

Country Link
US (1) US7750020B2 (es)
EP (1) EP1735322B1 (es)
JP (1) JP4700684B2 (es)
KR (1) KR100830007B1 (es)
CN (1) CN1960995B (es)
AR (1) AR050913A1 (es)
AT (1) ATE524479T1 (es)
AU (1) AU2005229416B2 (es)
BR (1) BRPI0509573A (es)
CA (1) CA2560689C (es)
EC (1) ECSP066894A (es)
IL (1) IL178151A0 (es)
MA (1) MA28528B1 (es)
NO (1) NO20064929L (es)
PE (1) PE20061353A1 (es)
PT (1) PT1735322E (es)
RU (1) RU2412192C2 (es)
TN (1) TNSN06315A1 (es)
WO (1) WO2005095418A1 (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
CA2498089A1 (en) * 2002-10-03 2004-06-17 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
CN101098876A (zh) * 2004-04-02 2008-01-02 诺瓦提斯公司 噻唑并吡啶衍生物、包含它们的药物形式以及治疗葡糖激酶介导的病症的方法
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
WO2007053657A1 (en) * 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
CN101321747A (zh) * 2005-11-01 2008-12-10 詹森药业有限公司 作为葡萄糖激酶变构调节剂的取代的环烷基吡咯酮类
EP1960385A1 (en) 2005-11-01 2008-08-27 Janssen Pharmaceutica N.V. Substituted dihydroisoindolones as allosteric modulators of glucokinase
JP2009518286A (ja) * 2005-11-01 2009-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ グルコキナーゼのアロステリックモジュレーターとしてのジヒドロイソインドロン
US8247442B2 (en) 2006-03-29 2012-08-21 Purdue Pharma L.P. Benzenesulfonamide compounds and their use
US8937181B2 (en) 2006-04-13 2015-01-20 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2007118853A1 (en) 2006-04-13 2007-10-25 Euro-Celtique S.A. Benzenesulfonamide compounds and their use as blockers of calcium channels
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CA2657566A1 (en) 2006-07-24 2008-01-31 F. Hoffmann-La Roche Ag Pyrazoles as glucokinase activators
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
EP2116533B1 (en) * 2007-03-07 2013-07-10 Kyorin Pharmaceutical Co., Ltd. Glucokinase activator
WO2008119734A2 (en) * 2007-03-29 2008-10-09 Novartis Ag Process for the manufacture of organic compounds
US8399486B2 (en) 2007-04-09 2013-03-19 Purdue Pharma L.P. Benzenesulfonyl compounds and the use thereof
US8765736B2 (en) 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
AU2008310519B2 (en) * 2007-10-08 2013-05-02 Advinus Therapeutics Private Limited Acetamide derivatives as glucokinase activators, their process and medicinal applications
CN101417987B (zh) * 2007-10-24 2011-07-13 山东轩竹医药科技有限公司 具有磺酰胺甲酰哌嗪结构的dpp-iv抑制剂
BRPI0906888A2 (pt) 2008-01-18 2015-11-03 Astellas Pharma Inc derivado de fenilacetamida
US7741327B2 (en) 2008-04-16 2010-06-22 Hoffmann-La Roche Inc. Pyrrolidinone glucokinase activators
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
ES2542753T3 (es) 2008-04-28 2015-08-10 Kyorin Pharmaceutical Co., Ltd. Derivado de ciclopentilacrilamida
CL2009001203A1 (es) 2008-05-16 2009-10-23 Takeda San Diego Inc Compuestos derivados de indazol y pirazol sustituidos; composicion farmaceutica de dichos compuestos; kit farmaceutico; y su uso como activadores de la glucoquinasa para tratar enfermedades metabolicas tales como hiperglicemia, diabetes, dislipidemias, obesidad, sindrome metabolico x y enfermedades cardiovasculares.
CA2735184C (en) * 2008-09-11 2013-05-28 Pfizer Inc. Heteroaryls amide derivatives and their use as glucokinase activators
DK2406253T3 (da) 2009-03-11 2013-08-12 Pfizer Benzofuranylderivater anvendt som glucokinase-inhibitorer
JP6073677B2 (ja) 2009-06-12 2017-02-01 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 縮合複素環式化合物およびそれらの使用
US8222416B2 (en) 2009-12-14 2012-07-17 Hoffmann-La Roche Inc. Azaindole glucokinase activators
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
EP2553086B1 (en) 2010-03-31 2017-04-19 The Scripps Research Institute Reprogramming cells
CA2856291C (en) 2011-11-17 2020-08-11 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
WO2013173382A1 (en) * 2012-05-15 2013-11-21 Amgen Inc. Benzothiophene sulfonamides and other compounds that interact with glucokinase regulatory protein
US10112927B2 (en) 2012-10-18 2018-10-30 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
JP6491202B2 (ja) 2013-10-18 2019-03-27 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド サイクリン依存性キナーゼ７（ｃｄｋ７）の多環阻害剤
EP3057955B1 (en) 2013-10-18 2018-04-11 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
AU2016319125B2 (en) 2015-09-09 2021-04-08 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2226811T3 (es) * 1999-03-29 2005-04-01 F. Hoffmann-La Roche Ag Activadores de glucoquinasa.
RU2242469C2 (ru) * 1999-03-29 2004-12-20 Ф.Хоффманн-Ля Рош Аг Активаторы глюкокиназы
US6610846B1 (en) 1999-03-29 2003-08-26 Hoffman-La Roche Inc. Heteroaromatic glucokinase activators
US6320050B1 (en) * 1999-03-29 2001-11-20 Hoffmann-La Roche Inc. Heteroaromatic glucokinase activators
US6353111B1 (en) 1999-12-15 2002-03-05 Hoffmann-La Roche Inc. Trans olefinic glucokinase activators
AU2001252270B2 (en) * 2000-05-03 2005-12-15 F. Hoffmann-La Roche Ag Hydantoin-containing glucokinase activators
KR100502033B1 (ko) 2000-05-03 2005-07-25 에프. 호프만-라 로슈 아게 알키닐 페닐 헤테로방향족 글루코키나제 활성제
CN1245394C (zh) * 2000-05-08 2006-03-15 霍夫曼-拉罗奇有限公司 作为葡糖激酶激活剂的取代的苯乙酰胺及其用途
US6489485B2 (en) * 2000-05-08 2002-12-03 Hoffmann-La Roche Inc. Para-amine substituted phenylamide glucokinase activators
PT1283830E (pt) * 2000-05-08 2008-08-18 Hoffmann La Roche Activadores da glucoquinase de fenilamida substituída com para-amino
AU2001287600B2 (en) * 2000-07-20 2006-07-13 F. Hoffmann-La Roche Ag Alpha-acyl and alpha-heteroatom-substituted benzene acetamide glucokinase activators
US6369232B1 (en) * 2000-08-15 2002-04-09 Hoffmann-La Roche Inc. Tetrazolyl-phenyl acetamide glucokinase activators
US6433188B1 (en) * 2000-12-06 2002-08-13 Wendy Lea Corbett Fused heteroaromatic glucokinase activators
CA2429642C (en) * 2000-12-06 2007-11-20 F. Hoffmann-La Roche Ag Fused heteroaromatic glucokinase activators
US6482951B2 (en) 2000-12-13 2002-11-19 Hoffmann-La Roche Inc. Isoindolin-1-one glucokinase activators
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
US6911545B2 (en) 2001-12-19 2005-06-28 Hoffman-La Roche Inc. Crystals of glucokinase and methods of growing them
EP1458382A1 (en) 2001-12-21 2004-09-22 Novo Nordisk A/S Amide derivatives as gk activators
WO2003080585A1 (fr) * 2002-03-26 2003-10-02 Banyu Pharmaceutical Co., Ltd. Derive aminobenzamide
ATE346056T1 (de) 2002-04-26 2006-12-15 Hoffmann La Roche Substituierte phenylacetamide und deren verwendung als glucokinaseaktivatoren
AU2003235307A1 (en) 2002-05-16 2003-12-02 Banyu Pharmaceutical Co., Ltd. Crystal of glucokinase protein, and method for drug design using the crystal
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
ES2293005T3 (es) 2002-10-03 2008-03-16 F. Hoffmann-La Roche Ag Indol-3-carboxamidas como activadores de la glucocinasa.
CA2498089A1 (en) * 2002-10-03 2004-06-17 Novartis Ag Substituted (thiazol-2-yl) -amide or sulfonamide as glycokinase activators useful in the treatment of type 2 diabetes
US7132425B2 (en) 2002-12-12 2006-11-07 Hoffmann-La Roche Inc. 5-substituted-six-membered heteroaromatic glucokinase activators
WO2004063194A1 (en) 2003-01-06 2004-07-29 Eli Lilly And Company Heteroaryl compounds
EP1585739B1 (en) 2003-01-06 2011-04-20 Eli Lilly And Company Substituted arylcyclopropylacetamides as glucokinase activators
WO2004072066A1 (en) 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
AR045414A1 (es) 2003-02-13 2005-10-26 Banyu Pharma Co Ltd Derivados de 2 - piridincarboxamida y composiciones farmaceuticas que las contienen.
CA2516407C (en) 2003-02-26 2013-07-09 Banyu Pharmaceutical Co., Ltd. Heteroarylcarbamoylbenzene derivatives
CN101098876A (zh) * 2004-04-02 2008-01-02 诺瓦提斯公司 噻唑并吡啶衍生物、包含它们的药物形式以及治疗葡糖激酶介导的病症的方法
WO2005103021A1 (en) 2004-04-21 2005-11-03 Prosidion Limited Tri(cyclo) substituted amide compounds
CA2576407A1 (en) 2004-08-12 2006-02-16 Prosidion Limited Substituted phenylacetamides and their use as glucokinase activators
KR101066882B1 (ko) 2004-12-03 2011-09-26 트랜스테크 파르마, 인크. 헤테로방향족 글루코키나제 활성화제
GT200600429A (es) 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) 2005-09-30 2007-05-21 Compuestos organicos

Also Published As

Publication number Publication date
EP1735322A1 (en) 2006-12-27
IL178151A0 (en) 2006-12-31
BRPI0509573A (pt) 2007-09-25
AU2005229416B2 (en) 2009-03-26
PE20061353A1 (es) 2006-12-29
US20080103167A1 (en) 2008-05-01
US7750020B2 (en) 2010-07-06
PT1735322E (pt) 2012-01-12
EP1735322B1 (en) 2011-09-14
WO2005095418A1 (en) 2005-10-13
CN1960995A (zh) 2007-05-09
CA2560689A1 (en) 2005-10-13
JP2007530632A (ja) 2007-11-01
RU2412192C2 (ru) 2011-02-20
AR050913A1 (es) 2006-12-06
TNSN06315A1 (en) 2007-12-03
RU2006138433A (ru) 2008-05-10
JP4700684B2 (ja) 2011-06-15
CN1960995B (zh) 2010-12-08
AU2005229416A1 (en) 2005-10-13
NO20064929L (no) 2006-12-20
ATE524479T1 (de) 2011-09-15
KR100830007B1 (ko) 2008-05-15
KR20060131955A (ko) 2006-12-20
MA28528B1 (fr) 2007-04-03
CA2560689C (en) 2011-03-01

Similar Documents

Publication Publication Date Title
ECSP066894A (es) Derivados de sulfonamida-tiazolpiridina como activadores de glucocinasa utiles en el tratamiento de diabetes de tipo 2
GT200600429A (es) Compuestos organicos
UY28005A1 (es) Indol -3-carboxamidas como activadores de glucoquinasa (gk)
CR9078A (es) Derivado de bencimidazol ariloxi-sustituidos
CO6270223A2 (es) Derivados de piridin-2-ilamino-1,2,4 tiadiazol como activadores de glucocinasa para el tratamiento de diabetes mellitus
GT200600092A (es) Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer
DOP2002000438A (es) Inhibidores de la dipetidil peptidasa beta-amino heterocíclica para el tratamiento o la prevención de la diabetes
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
ATE521608T1 (de) Glucokinaseaktivatoren
NI200700169A (es) Derivados del pirimidinil y piridinil sustituidos como moduladores del metabolismo y el tratamiento de desordenes relacionados con el mismo.
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
ECSP067095A (es) Compuestos y metodos para el tratamiento de dislipidemia
UY28923A1 (es) Compuestos terapéuticos: piridina como estructura base
NI200700032A (es) Derivados arilsulfonilestilbeno para tratamiento de insomnio y afecciones relacionadas
ECSP034811A (es) Derivados heterocicliloxi-, -tioxi - y - aminobenzazole tales como ligandos 5-hidroxitriptamina-6
UY29258A1 (es) Ácidos hidroxibifenilcarboxílicos y derivados, procedimientos para prepararlos y su uso
ECSP045156A (es) Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6
BRPI0509543A (pt) derivados de tiazolopiridina, condições farmacêuticas que contêm os mesmos e métodos para tratar condições mediadas por glucocinase
UY28774A1 (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes.
UY28098A1 (es) Derivados de anilinopirazol útiles en el tratamiento de la diabetes
DK1809270T3 (da) 5,6,7-trihydroxyheptansyre og analoger til behandling af okulære sygdomme og sygdomme associeret med hyperproliferative og angiogeniske reaktioner
UY28448A1 (es) Benzoilureido-o-benzoilamidas sustituidas, procedimiento para su preparación y su uso.
CY1116330T1 (el) Αναλογα 2-αμινοπυριδινης ως ενεργοποιητες γλυκοκινασης
ECSP045157A (es) Derivados de azaindolilalquilamina como ligandos 5-hidroxitriptamina-6